Gastroenterology Department, Timone Hospital, Marseille, France.
Endoscopy and Gastroenterology Departement, Paoli-Calmettes Institute, Marseille, France.
Dig Liver Dis. 2018 Feb;50(2):189-194. doi: 10.1016/j.dld.2017.09.121. Epub 2017 Sep 21.
Biliary obstruction secondary to colorectal cancer liver metastases is associated with a poor prognosis especially when chemotherapy cannot be re-started. The aim of this study was to determine the survival after biliary drainage and the associated prognostic factors.
Patients from two French centers were included retrospectively after first biliary endoscopic retrograde cholangiopancreatography or percutaneous transhepatic cholangiography drainage for biliary obstruction secondary to liver metastases of colorectal cancer, occurring during chemotherapy.
The final analysis included 69 patients. Overall median survival was 115 days. In univariate analysis, a previous liver surgery, technical and functional success of drainage and restarted chemotherapy were significantly associated with an improved survival. Chemotherapy was restarted after a median of 27 days. When drainage was efficient, survival improved from 33 to 262days (p<0.001). In multivariate analysis, significant protective factors for survival included previous a hepatectomy (HR 0.41) and functional success of the drainage (HR 0.29). Predictive factors for death included increased lines of chemotherapy (HR 1.68) and fever before drainage (HR 2.97).
This is the first study concerning the benefits of biliary drainage for malignant biliary obstruction during the course of chemotherapy for colorectal cancer. A successful biliary drainage leads to improved survival and allows achievement of chemotherapy for 70% of patients.
结直肠癌肝转移继发胆道梗阻与预后不良相关,尤其是在无法重新开始化疗的情况下。本研究旨在确定胆道引流后的生存情况及其相关的预后因素。
回顾性纳入在化疗过程中因结直肠癌肝转移而继发胆道梗阻,首次行胆道内镜逆行胰胆管造影术或经皮经肝胆管引流术的 2 家法国中心的患者。
最终分析纳入 69 例患者。总体中位生存期为 115 天。单因素分析显示,既往肝切除术、引流的技术和功能成功以及重新开始化疗与生存改善显著相关。中位时间为 27 天后开始化疗。当引流有效时,生存时间从 33 天延长至 262 天(p<0.001)。多因素分析显示,生存的显著保护因素包括既往肝切除术(HR 0.41)和引流的功能成功(HR 0.29)。死亡的预测因素包括化疗线数增加(HR 1.68)和引流前发热(HR 2.97)。
这是第一项关于结直肠癌化疗过程中恶性胆道梗阻行胆道引流获益的研究。胆道引流成功可改善生存,并使 70%的患者能够实现化疗。